Celltrion has revealed a filing for a biosimilar version of Eylea (aflibercept) in the US, stating that it has filed its CT-P42 candidate with the US Food and Drug Administration to cover all indications of the original ophthalmic brand, excluding pediatric indications.
Celltrion Is Latest To File Eylea Rival In US
Korean Firm Submits Application For CT-P42 Aflibercept Biosimilar To US FDA
Celltrion has become the latest firm to reveal that it has filed a biosimilar Eylea application with the US FDA in the form of its CT-P42 aflibercept candidate.
More from Biosimilars
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
More from Products
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.